Boston Scientific revenue expected to drop 2%, Medigus completes $7.1M public offering & more – 5 GI/endoscopy company key notes

Here are five recent news updates on key gastroenterology and endoscopy companies.

AbbVie could get 13 percent to 18 percent of hepatitis C market share, according to a Barron's report.

Boston Scientific will report its second quarter financial results on July 23. Financial analysts expect the company's revenue to drop 2 percent year-over-year to $1.83 billion, according to a Forbes report.

Medigus, the medical device company behind the MUSE system, completed its previously announced public offering in Israel. The public offering of 70,525 units at a purchase price of 380 New Israeli Shekels per unit resulted in gross proceeds of approximately NIS 26.8 million, or $7.1 million.

Medigus is progressing toward registration for the receipt of China Food and Drug Administration approval. Sinopharm currently owns the distribution rights for the MUSE system in China.

Valeant Pharmaceuticals CFO and executive vice president Howard Schiller resigned, according to a Street Insider report. Mr. Schiller will remain on the company's board of directors and serve as a consultant to the company.

If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at

More articles on gastroenterology:
Boston Scientific adds new board leadership, EndoChoice earns "strong buy" rating & more –5 GI/endoscopy company key notes
Dr. Jason Bratcher joins Berkshire Health Systems
5 most read GI stories – July 13 to July 17

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months